Fig. 1

In vivo transposon-based gene delivery into the liver of Fah^−/− and WT mice. a Schematic representation of the Sleeping Beauty (SB) transposon-based cloning platform and animal treatments. Black arrows, SB transposon inverted terminal repeats; red arrows, promoters. b Fah and EGFP immunostainings of liver sections from Fah^−/− mice 3 months after NTBC withdrawal. c Monitoring the amount of transcripts A and B following in vivo gene delivery. Liver RNA samples were collected from Fah^−/− mice at 3 months post-treatment. Samples were tested using Fah- and EGFP-specific RT-qPCR assays. Results were normalized to measurements of the ribosomal protein L27 (Rpl27) transcript as input control and data were presented as the mean ± standard deviation (SD) (n = 3) (see Additional file 2 for individual data values and statistics). d Live bioluminescence imaging of Fah^−/− and WT mice following in vivo gene delivery. Bioluminescence signals were obtained using an IVIS Lumina III imaging system at 3, 7, 14, 28, 56, and 84 days post-treatment. e Kinetics of bioluminescence changes during the first 3 months after gene delivery. For each experimental animal, the average radiance (photons/second/cm²/steradian (sr) [p/s/cm²/sr]) of circular regions of the same size covering the liver area was used for plotting. The numerical values were presented as box diagram from lowest to highest values with line at mean (n = 3) (see Additional file 2 for individual data values and statistics)